Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21910684 | 0.81 | SIGMAR1 (0.46) | SIGMAR1KCNH2DRD2DRD3SLC6A3 | |
| SCHEMBL25882893 | 0.80 | KDM4E (0.49) | SIGMAR1ALDH1A1SMN1; SMN2DPP8DPP4 | |
| SCHEMBL21831264 | 0.78 | MAPK14 (0.35) | ALDH1A1DPP8DPP4DPP7KCNH2 | |
| SCHEMBL21831647 | 0.78 | MAPK14 (0.35) | ALDH1A1DPP8DPP4DPP7KCNH2 | |
| SCHEMBL25883261 | 0.77 | NR3C2 (0.39) | ALDH1A1SMN1; SMN2DPP4DPP7SLC6A3 | |
| SCHEMBL25882219 | 0.76 | SIGMAR1 (0.40) | SIGMAR1ALDH1A1POLBSMN1; SMN2DPP8 | |
| SCHEMBL25881984 | 0.76 | SIGMAR1 (0.40) | SIGMAR1ALDH1A1POLBSMN1; SMN2DPP8 | |
| SCHEMBL25882229 | 0.76 | SIGMAR1 (0.40) | SIGMAR1ALDH1A1POLBSMN1; SMN2DPP8 | |
| SCHEMBL25881977 | 0.76 | SIGMAR1 (0.40) | SIGMAR1ALDH1A1POLBSMN1; SMN2DPP8 | |
| SCHEMBL29923023 | 0.73 | TACR1 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | SIGMAR1 3220/4885ALDH1A1 3814/4885POLB 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.